Neurocrine bets $2B on Takeda’s psychiatry drugs
Neurocrine Biosciences has licensed seven psychiatry drug programs from Takeda in a deal valued at more than $2B, adding diversity to Neurocrine’s pipeline. Three of the seven Takeda programs are in human trials. Neurocrine now has full rights to those drugs and will develop and commercialize them.
Neurocrine will pay Takeda $120M upfront and could tack on another $1.9B in development and commercial milestones later.
